Influence of gender on survival in patients with stage I malignant melanoma

Journal of the American Academy of Dermatology

Volumn 26, Issue 3, 1992, Pages 429-440

  Vossaert, Katrien A ^a   Silverman, Mark K ^a   Kopf, Alfred W ^a   Bart, Robert S ^a   Rigel, Darrell S ^a   Friedman, Robert J ^a   Levenstein, Marcia ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SKIN ULCER; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME;

EID: 0026573503     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/0190-9622(92)70068-Q     Document Type: Article

References (112)

1. End results in the treatment of malignant melanoma: a report of 1190 cases
2. Malignant melanoma: a clinicopathologic analysis of the criteria for diagnosis and prognosis
3. Studies on melanoma. II. Sex and survival in human melanoma
4. Biological aspects of human malignant melanoma
5. Malignant melanoma: a review of 10 years' experience in Glasgow, Scotland
6. Cutaneous melanoma: a twenty-year retrospective study with clinicopathologic correlation
7. A clinicopathologic study of prognostic factors in cutaneous malignant melanoma
8. Prognosis in malignant melanoma of the skin: significance of stage of disease, anatomical site, sex, age and period of diagnosis
9. Evaluation de facteurs pronostiques du melanome malin par la methode actuarielle
10. Malignant melanoma of the lower extremity: evaluation of 453 patients
11. Histologic features of tumors and the female superiority in survival from malignant melanoma
12. Malignant melanoma: influence of site of lesion and age of patient in the female superiority in survival
13. 8-Year survival in malignant melanoma related to sex and tumor location
14. Malignant melanoma of the skin. I. The association of tumor depth and type, and patient's sex, age and site with survival
15. Prognostic groups of patients with Stage I melanoma
16. Prognostic significance of the patient's sex, tumor site, and mitotic rate in thin (<1.5 mm) melanoma
17. Multivariate analysis: some guidelines for physicians
18. Malignant melanoma: a multivariate analysis of prognostic factors
19. Prognostic factors in cutaneous malignant melanoma in Stage I
20. A comparison of prognostic factors and surgical results in 1786 patients with localized (Stage I) melanoma treated in Alabama, USA, and New South Wales, Australia
21. Survival with malignant melanoma: a regression analysis of prognostic factors
22. Prognostic index for clinical Stage I cutaneous malignant melanoma
23. Melanoma in Italy: experience at the National Cancer Institute of Milan
24. Melanoma in the Southeastern United States: experience at the Duke Medical Center
25. An analysis of prognostic factors in 4000 patients with cutaneous melanoma
26. Melanoma in Germany: experience at the university of Erlangen, Nurnberg
27. Comparison of prognostic factors for survival and recurrence in malignant melanoma of the skin, clinical Stage I
28. Therapeutic and clinicopathologic factors in the survival of 1469 patients with primary cutaneous malignant melanoma in clinical Stage I
29. Sex differences in presentation of cutaneous malignant melanoma and in survival from Stage I disease
30. BANS. A cutaneous region with no prognostic significance in patients with melanoma
31. Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with Stage I disease
32. Maximum utilization of the life table method in analyzing survival
33. Regression model and life tables
34. The PHGLM procedure
35. A multifactorial analysis of melanoma. III. Prognostic factors in melanoma patients with lymph nodemetastases (Stage II)
36. Malignant melanoma patients with positive nodes and relatively good prognosis: microstaging retains prognostic significance in clinical Stage I melanoma patients with metastases to regional nodes
37. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes
38. Primary melanoma thickness correlated with regional lymph node metastases
39. A multifactorial analysis of melanoma
40. The prognostic significance of ulceration of cutaneous malignant melanoma
41. “Microscopic satellites” are more highly associated with regional lymph node metastases than is primary melanoma thickness
42. Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases
43. Survival of cutaneous malignant melanoma patients at University of Iowa hospitals: 1950–1974
44. Survival and prognostic factors of patients with skin melanoma
45. Long-term survival in malignant melanoma with special reference to age and sex as prognostic factors
46. The association between anatomic site and survival in malignant melanoma: an analysis of 12353 cases from the Swedish Cancer Registry
47. Low and high-risk malignant melanoma. II. Multivariate analyses for a prognostic classification
48. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous malignant melanoma
49. Prognosis for recurrent Stage I malignant melanoma
50. Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics
51. Malignant melanoma of the skin: prognostic factors derived from a multifactorial analysis of 293 cases
52. Cigarette smoking and malignant melanoma
53. Malignant melanoma and pregnancy
54. Malignant melanoma arising during pregnancy
55. A prognostic model for clinical Stage I melanoma of the lower extremity
56. A prognostic model for clinical Stage I melanoma of the trunk
57. A prognostic model for clinical Stage I melanoma of the upper extremity
58. Delayed regional lymph node dissection in Stage I melanoma of the skin of the lower extremities
59. Head and neck melanoma in 534 clinical Stage I patients
60. Prognostic factors in head and neck melanoma
61. Prognostic factors for melanoma patients with lesions 0.76–1.69 mm in thickness
62. Prognostic factors for patients with clinical Stage I melanoma of intermediate thickness (1.51–3.99 mm)
63. A multivariate analysis of prognostic factors for melanoma patients with lesions ≥3.65 mm in thickness
64. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma
65. Thin level IV malignant melanoma: a subset in which level is the major prognostic indicator
66. The role of lymph node dissection for clinical Stage I malignant melanoma of intermediate thickness (1.51–3.99 mm)
67. Nevomelanocytic proliferations in association with cutaneous malignant melanoma: a multivariate analysis
68. Lentigo maligna melanoma has no better prognosis than other types of melanoma
69. The extent of primary melanoma excision: a re-evaluation of how wide is wide?
70. Does biopsy type influence survival in clinical stage I cutaneous melanoma?
71. Prognosis of clinical Stage I melanoma patients with positive elective regional node dissection
72. A randomized prospective clinical trial of adjuvant C-parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factor analysis and preliminary results of immunotherapy
73. Early death from clinical Stage I melanoma
74. Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical Stage I patients
75. Predictors of late deaths among patients with clinical Stage I melanoma who have not had bony or visceral metastases within the first 5 years of the diagnosis
76. Effect of anatomical location on prognosis in patients with clinical Stage I melanoma
77. Regression in malignant melanoma
78. Influence of anatomic location on prognosis of malignant melanoma: an attempt to verify the BANS model
79. Prognostic index for malignant melanoma
80. Prognosis of Stage I melanoma of the skin
81. A multifactorial analysis of melanoma. II. Prognostic factors in patients with Stage I (localized) melanoma
82. Sex related survival differences in instances of melanoma
83. Melanoma in Sweden: experience at the University of Göteborg
84. Melanoma in the Southern United States: experience at the University of Alabama in Birmingham
85. Endocrine influences on survival from malignant melanoma
86. Patient and physician delay in melanoma diagnosis
87. Sex differences in survival from cutaneous melanoma
88. Malignant melanoma: sex differences in survival after evidence of distant metastasis
89. Malignant melanoma: an androgen-dependent tumor?
90. Late recurrence of malignant melanoma: a report of five cases, a review of the literature and a study of associated factors
91. Epidemiology of pre-invasive and invasive malignant melanoma in Western Australia
92. Sun and malignant melanoma
93. Cutaneous melanoma in relation to intermittent and constant sun exposure. The Western Canada Melanoma Study
94. Risk factors for the development of malignant melanoma. I. Review of case control studies
95. Incidence trends in the Nordic countries: effects of sun exposure
96. Cutaneous factors related to the risk of malignant melanoma
97. Number of melanocytic nevi as a major risk factor for malignant melanoma
98. Anzahl and verteilung von Naevuszellnaevi bei Patienten mit malignem Melanom
99. The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population
100. Cutaneous melanoma in relation to exogenous hormones and reproductive factors
101. Malignant melanoma and oral contraceptive use among women in California
102. The prognosis for malignant melanoma in the pregnant woman
103. The effect of pregnancy on hormone levels and receptors in malignant melanoma
104. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women
105. Prognostic significance of pregnancy in Stage I melanoma
106. Malignant melanoma arising during pregnancy: a study of 100 patients
107. Lack of effect of pregnancy on outcome of melanoma
108. Oestrogen receptors in human malignant melanoma
109. Estrogen receptor in malignant melanoma: Fact or artifact?
110. Sex steroid receptor analysis in human melanoma